RELMARQA
Live / Applied — First extension granted (statement of use) (as of 19 Aug 2025)
What this means for you
Not registered yet, but its 18 Nov 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98858243
- Mark type
- Stylized text
- Filed
- 18 Nov 2024
- Published for opposition
- 29 Apr 2025
- Attorney of record
- Joel R. Feldman
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of psychiatric and neurological diseases and disorders; pharmaceutical preparations for the treatment of Cushing's syndrome and Cushing's disease; pharmaceutical preparations for the treatment of cancer, liver disorders, oncologic, endocrine, metabolic, cardiovascular, ophthalmic, and gastroenterologic diseases and disorders
Owner
- Corcept Therapeutics Incorporated, Redwood City, CA, US
- Corcept Therapeutics Incorporated, Menlo Park, CA, US
Prosecution history
- 21 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Aug 2025 — SOU EXTENSION 1 GRANTED
- 19 Aug 2025 — SOU EXTENSION 1 FILED
- 19 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 24 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 29 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Apr 2025 — PUBLISHED FOR OPPOSITION
- 23 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 31 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 31 Mar 2025 — ASSIGNED TO EXAMINER
- 18 Nov 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 18 Nov 2024 — NEW APPLICATION ENTERED